Experimental evidence suggests HNF1a regulates UGT expression. This study investigates (1) whether the variability in HNF1a expression is associated with the variability in UGT1A1, UGT1A9 and UGT2B7 expression in human livers and (2) the functionality of 12 HNF1a variants using mRNA expression as phenotype. Controlling for known UGT variation in cis-acting elements known to affect UGT expression, we demonstrate that a combination of HNF1a mRNA levels and UGT genotype predicts variance in UGT expression to a higher extent than UGT genotype alone. None of the HNF1a polymorphisms studied, however, seem to have an effect on HNF1a, UGT1A1, UGT1A9 and UGT2B7 expression, ruling out their functional role. Our data provide evidence for HNF1a being a determinant of UGT1A1, UGT1A9 and UGT2B7 mRNA expression. However, the amount of UGT intergenotype variability explained by HNF1a expression appears to be modest, and further studies should investigate the role of multiple transcription factors.
Introduction
Glucuronidation by the uridine diphosphate-glucuronosyltransferase (UGT) enzymes is a major metabolic pathway that facilitates the elimination of a large variety of molecules into urine and bile by increasing their water solubility. The UGT1 gene codes for nine functional UGT1A enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10) generated through a process of RNA splicing of one of the multiple first exons to the set of common exons 2-5. The UGT2 family is encoded by separate homologous genes and is subdivided into two subfamilies: UGT2A (encoding UGT2A1) and UGT2B (encoding proteins UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17 and UGT2B28). Most UGTs are expressed in the liver but they can also be found in extrahepatic tissues.
Genetic polymorphisms in UGTs have been associated with interindividual variability in glucuronidation. The genetic variation in UGT1A1 is the most extensively studied. UGT1A1 gene transcriptional activity is affected by the length of the TATA box in the promoter, where a larger number of TA repeats results in reduced transcriptional activity. Homozygosity for the (TA) 7 allele (UGT1A1*28) is associated with Gilbert's syndrome (a mild form of conjugated hyperbilirubinemia) 1, 2 and predisposition to severe toxicity of the anticancer drug irinotecan. 3, 4 Even though the effect of the UGT1A1*28 allele on the UGT1A1 glucuronidation rates in humans is well known, the phenotypic variability within each genotypic group remains high. 4, 5 Similar to UGT1A1, the UGT1A9 and UGT2B7 isoforms are highly expressed in the liver and play an important role in the hepatic glucuronidation of numerous drugs. Multiple studies have been conducted to evaluate the functional consequences of common polymorphisms in UGT1A9 and UGT2B7, although the results to date have been inconsistent. [5] [6] [7] [8] [9] [10] It can be hypothesized that the phenotypic variability in UGTs that remains unaccounted for by cis-acting genetic polymorphisms resides in the variability in transcription factors. Initiation of transcription is an integrated and complex mechanism involving both cis-acting elements and trans-acting factors. Transcription factors involved in the regulation of UGT constitutive expression include the hepatocyte nuclear factor 1 (HNF1), the octamer transcription factor 1 (Oct-1), the pre-B-cell homeobox factor 2 (Pbx2), the caudal-related homeodomain protein 2 (Cdx2, an intestine-specific transcription factor) and Prep1. [11] [12] [13] [14] [15] [16] UGT regulation by hormones and xenobiotics is mediated through the aryl hydrocarbon receptor (AhR), the constitutive androgen receptor (CAR), the pregnane X receptor (PXR), the farnesoid X receptor, the peroxisome proliferated-activated receptors and transcription factors that respond to stress. 17 The HNF1 family is comprised of HNF1a and HNF1b, which increase gene transcription by binding as homodimers or heterodimers to DNA sequences in target genes. HNF1a is well conserved among species and is the predominant form expressed in the human liver. 18 Experimental evidence suggests a prominent role of HNF1a as a trans-acting factor regulating UGT expression. HNF1a binds and activates the proximal promoters of several human UGTs, including UGT1A1, UGT1A9 and UGT2B7. 11, 13, 15, 16, 19 HNF1a is polymorphic. The I27L (79A4C) variant, a common missense polymorphism in HNF1a, is located in the dimerization domain of the protein. 20 79A4C is associated with insulin resistance and glucose intolerance as well as with differences in high-density lipoprotein cholesterol among individuals. [20] [21] [22] The molecular function of this variant has not been established but preliminary studies showed that luciferase UGT2B17 activity was reduced after cells were co-transfected with HNF1a 79A4C compared to constructs without this variant.
14 Additionally, HNF1a rare variants have been associated with maturity onset diabetes of the young (MODY3). 23 The effect of HNF1a genetic variation on its mRNA expression in human liver, as well as its association with the expression of UGTs known to be regulated by HNF1a, has never been studied.
This study had two aims: (1) to investigate whether HNF1a mRNA expression levels predict mRNA expression level variability in UGT1A1, UGT2B7 and UGT1A9 while taking into account the known effect of cis-acting variants on UGT expression and (2) to determine whether any of the 12 HNF1a polymorphisms typed in normal livers might influence the mRNA expression of HNF1a and the UGTs of interest.
Results

Effect of HNF1a genotypes on HNF1a expression
The median (not log-transformed) hepatic mRNA level of HNF1a was 254 (range 30-944, n ¼ 53). The median mRNA level of 18S was 1.18 (range 0.18-1.84, n ¼ 54). The frequencies of the HNF1a variants are listed in Table 1 . All alleles were in Hardy-Weinberg equilibrium, and their frequencies were comparable to the data in the HapMap for the CEPH Caucasians. None of the HNF1a genotypes had a significant effect (P40.1) on the expression of HNF1a.
Effect of UGT genotypes on UGT expression
The median (not log-transformed) mRNA levels of UGT1A1, UGT1A9 and UGT2B7 were 759 (range 71-15,712, n ¼ 54), 520 (range 6-14,303, n ¼ 44) and 1263 (range 17-17.245, n ¼ 54), respectively. Analysis of the linear relationship between the mRNA levels of the UGTs showed that the UGT1A1 mRNA levels were significantly and moderately related to those of UGT1A9 (r 2 ¼ 0.49, Po0.0001, n ¼ 44; Figure 1a ) and UGT2B7 (r 2 ¼ 0.39, Po0.0001, n ¼ 54; Figure  1b) . Similarly, the mRNA content of UGT1A9 and UGT2B7 were significantly correlated (r 2 ¼ 0.54, Po0.0001, n ¼ 44; Figure 1c ). Similar results were obtained in partial correlations performed to adjust for a potential confounding effect of 18S mRNA levels (data not shown).
The genotype frequencies of the UGT variants are shown in Table 1 . The alleles were in Hardy-Weinberg equilibrium. The association between UGT1A1*28 and UGT1A1 expression was best described by an additive model (r 2 ¼ 0.17, P ¼ 0.003, n ¼ 51; 6/6 ¼ 0, 6/7 ¼ 1, 7/7 ¼ 2; Figure 2 ). A recessive model (r 2 ¼ 0.08, P ¼ 0.07, n ¼ 43) described the relationship between UGT1A9*1b genotype and UGT1A9 expression (10/10: mean7s.d. ¼ 1.8870.92, n ¼ 6; 9/9 and 9/10: mean7s.d. ¼ 2.5870.83, n ¼ 37). The 985A4G Association between HNF1a expression/genotypes and UGT expression A modest and significant degree of correlation was observed between the mRNA levels of HNF1a and those of UGT1A1 (r 2 ¼ 0.14, P ¼ 0.006, n ¼ 53; Figure 3a ), UGT1A9 (r 2 ¼ 0.25, P ¼ 0.0006, n ¼ 44; Figure 3b ) and UGT2B7 (r 2 ¼ 0.18, P ¼ 0.001, n ¼ 53; Figure 3c ). Partial correlation analysis adjusting for 18S mRNA levels showed similar results (data not shown).
We tested whether the HNF1a single nucleotide polymorphisms (SNPs) have an effect on UGT expression. Significant although very weak associations were observed between two HNF1a variants and UGT1A1 expression. The HNF1a 79A4C variant was associated with UGT1A1 expression in a dominant model (r 2 Linear regression of UGT expression versus gender and history of intake of UGT inducers Higher mean mRNA levels were observed in females (n ¼ 13) compared with males (n ¼ 41) for both UGT2B7 (r 2 ¼ 0.10, P ¼ 0.02) and HNF1a (r 2 ¼ 0.07, P ¼ 0.05). No significant gender differences were observed for UGT1A1 and UGT1A9. History of medications and alcohol intake was available for 31 donors. Ten of these individuals received the UGT inducers phenobarbital and dexamethasone; nine donors were alcohol consumers. Smoking history was available for 43 individuals, 15 of which were smokers. No association was found between intake of any of these potential UGT inducers and the mRNA levels of any of the four genes (P40.05).
Multivariate analysis of UGT1A1, UGT1A9 and UGT2B7 mRNA expression Multivariate models were designed to identify covariates associated with the variability in UGT mRNA expression. The best models with the highest r 2 and with all independent variables having a Po0.05 are described on Table 2 . UGT1A1 expression was best predicted by a combination of HNF1a expression and UGT1A1*28 genotype (additive model: 6/6 ¼ 0, 6/7 ¼ 1, 7/7 ¼ 2). UGT1A9 expression could be best predicted by a combination of HNF1a expression and UGT1A9*1b genotype (recessive model: 9/9 and 9/10 ¼ 0, 10/10 ¼ 1). UGT2B7 expression can be best explained by a combination of HNF1a expression and the UGT2B7 985A4G polymorphism (dominant model: A/A ¼ 0, A/G and G/G ¼ 1). The percent of variance in UGT mRNA expression predicted by a combination of HNF1a mRNA expression and UGT genotype increased from 17% to 30%, 8% to 33%, and 9% to 26% for UGT1A1, UGT1A9 and UGT2B7, respectively, when compared with the variance predicted by UGT genotype alone. None of the HNF1a HNF1a regulation of UGT1A1, UGT1A9 and UGT2B7 J Ramírez et al variants were entered into the multivariate models as they were not significant at the P ¼ 0.10 level in the univariate analyses. Multivariate models including gender and UGT genotypes (without HNF1a expression) were also built, as we hypothesized that the gender-related differences observed in UGT expression might be due to the effect of gender on HNF1a expression. The only significant model was UGT2B7 mRNA ¼ À0.42*gender (male) (P ¼ 0.02) þ 0.37*UGT2B7 genotype (dominant) (P ¼ 0.04) (overall model: r 2 ¼ 0.18, P ¼ 0.008).
Discussion
We present evidence showing that the interindividual variability in UGT1A1, UGT1A9 and UGT2B7 is partly related to variation in HNF1a expression. Controlling for known UGT variation in cis-acting elements known to affect expression, we demonstrate that a combination of UGT genotype and HNF1a mRNA expression predicts variance in UGT expression to a higher extent than UGT genotype alone. The correlation observed between the mRNA expression of HNF1a and UGT2B7 is in agreement with a previous study showing a high correlation between the expression levels of these two genes in 12 human livers of Caucasian origin. 24 Although the strength of the correlation is not high, our results, obtained in a liver collection larger than that of Toide et al., 24 are in agreement with literature indicating that HNF1a can bind and activate promoters of UGT1A1, UGT1A9 and UGT2B7. 11, 13, 19 Although we did not measure protein expression and we cannot assume that a high level of correlation exists between mRNA and protein levels, the data from the literature are in support of a good correlation in UGT genes. For example, a strong correlation between UGT1A1 protein level and both UGT1A1 activity and mRNA level (r 2 ¼ 0.82 and 0.72, respectively) has been observed. 25 Similar correlations between mRNA and activity were also reported in another study for both UGT1A1 (r 2 ¼ 0.73) and UGT1A9 (r 2 ¼ 0.59). 26 This also holds true for UGT1A6 (r 2 ¼ 0.53 between mRNA and enzyme activity). 27 Besides clinical association studies, there are no data on the molecular function of the human variation of HNF1a. Our study is the first one to investigate whether several HNF1a variants might have functional consequences on gene expression. The HNF1a 79A4C variant does not seem to be associated with the phenotypic variability of HNF1a, UGT1A1, UGT1A9 and UGT2B7 mRNA expression although our sample set was limited to only four samples homozygous for the 79C allele. The weak correlation observed between HNF1a 79A4C and UGT1A1 expression might be spurious, as it is not consistent with previous association studies showing decreased pancreatic function [20] [21] [22] and reduced luciferase activity.
14 The tagging SNPs investigated did not have a functional effect on the gene expression of any of the four genes. It is unknown whether these polymorphisms have a functional effect. A study investigating whether tagging SNPs of HNF1a (including rs2071190 and rs3999413) were associated with type II diabetes showed negative results. 28 In addition, our study does not rule out the functional significance of the tagging SNPs of the HNF1a 29 Further studies are needed to elucidate the effects of these variants on protein expression, activity, dimerization, DNA binding properties as well as on constitutive/alternative splicing of the HNF1a mRNA.
In our study, common polymorphisms in UGT1A1, UGT1A9 and UGT2B7 affected their mRNA expression to different extents. There are numerous reports describing the functionality of UGT1A1*28, which reduces glucuronidation of bilirubin, SN-38 and benzo(a)pyrene-trans-7R,8R-dihydrodiol. 1, 4, [30] [31] [32] [33] However, a correlation with UGT1A1 mRNA expression in the liver had not been reported previously. In luciferase studies, a variable promoter region repeat (À118T 9410 , UGT1A9*1b) in UGT1A9 was reported to correlate with modest increases (1.4-to 2.6-fold) in protein expression, 10, 34 although no significant effect have been observed at the protein level. 9, 10 We found decreased UGT1A9 mRNA expression in individuals with the À118T 10/10 genotype. This suggests that the variant might negatively affect UGT1A9 transcription, although the observed effect did not reach statistical significance. These results are in agreement with the decreased glucuronidation activity previously observed in individuals with the À118(T) 10 allele observed in this same set of livers. 5 In addition to the effect of UGT genetic variants on gene expression, we detected a correlation among UGT1A1, UGT1A9 and UGT2B7 mRNA levels, which was expected as they are likely to share common regulatory pathways in the liver.
As phenobarbital, dexamethasone, alcohol and nicotine are inducers of glucuronidation, [35] [36] [37] [38] [39] [40] and gender may play a role in interindividual differences in drug metabolism, 41 we tested whether these variables were significant predictors of mRNA expression. A detailed drug history was not available for all samples, as this information is not always adequately collected from liver donors. Although gender differences were observed in the expression of UGT2B7 and HNF1a, replacement of HNF1a expression by gender in the UGT2B7 multivariate model decreased the level of correlation, indicating that HNF1a is a better predictor of UGT mRNA expression than gender.
Our results suggest that HNF1a is a determinant of UGT1A1, UGT1A9 and UGT2B7 hepatic expression, and contributes to their phenotypic variability. Nevertheless, there is still residual phenotypic variability in UGT expression that is unaccounted for by any of the factors investigated in this study, and further studies should investigate the role of multiple transcription factors. Other transcription factors known to regulate UGT expression independently from HNF1a should be tested in a similar model. For UGT1A1, these proteins include AP1, AP3, SP1, CEBPA, TITF1, TBP and CREB1 in the 600 bp 5 0 -flanking exon 1 area, 19, 42 and CAR, PXR and AhR in the PBREM cluster. 43, 44 To add to the complexity, intricate regulatory interactions exist among several transcription factors, whose expression is in turn regulated by several other trans-acting elements. It has been demonstrated that HNF1a-mediated activation of the UGT2B7 promoter is enhanced by the ubiquitous transcription factor Oct-1. 11 The transcription factors Pbx2-Pbx1 can downregulate activation of UGT2B17 by HNF1a by restricting access of HNF1a dimers to the DNA. Coactivators of HNF1a include CBP/p300, P/CAF, SRC-1 and RAC3. 45, 46 The GATA family of proteins is expressed in a wide range of tissues and has been demonstrated to interact with HNF1a in vitro and in vivo. 47 HNF4a has also been shown to regulate transcription of UGT1A9 and HNF1a in the liver, and both HNF4a and HNF1a seem to be coregulated. [48] [49] [50] [51] It is likely that the action of HNF1a is finely coordinated with that of other factors, and that UGT expression is the ultimate result of the interaction among multiple regulatory elements. Network-based approaches and more comprehensive studies of other transcription factors may clarify the contribution of each transcription factor in the regulation of UGT expression.
Materials and methods
Human liver samples DNA and RNA samples from 54 Caucasian donors were processed through Dr Mary Relling's Laboratory at St Jude Children's Research Hospital (Memphis, TN, USA). The hepatic tissue was provided by the Liver Tissue Procurement and Distribution System (funded by #NO1-DK-9-2310) and by the Cooperative Human Tissue Network. Donor livers were procured for possible transplant with approval of human subjects. Organs were flushed, in situ, with a cold storage solution such as University of Wisconsin solution. Livers were placed on wet ice and sent to isolation lab. Total cold ischemic time was usually less than 24 h. Pieces of liver tissue not used for cell isolation were snap frozen in liquid nitrogen and stored at À80 1 until used for DNA and RNA isolation. To insure that the liver tissue was viable, we relied on the viability of the cells isolated from a different portion of the same organ and the integrity of the RNA. All livers were treated identically.
Real-time PCR
UGT and HNF1a mRNA levels were measured by two-step real-time PCR using the Mx3000P system (Stratagene, Cedar Creek, TX, USA). Integrity of the RNA samples was verified by agarose gel electrophoresis. cDNA was synthesized in 20 ml reaction volumes using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA) and 2 mg of total RNA. The thermal profile was as follows: 251C for 5 min, 421C for 30 min, and 851C for 5 min. 18S was used as the control gene. 18S cDNA was prepared using the highcapacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) and following the manufacturer's instructions. The thermal profile consisted of 251C for 10 min and 371C for 2 h. All 54 cDNA samples were synthesized in a single experiment, and stored at -801C until further analysis. Real-time PCR reactions were performed using IQSYBR Green Supermix (Bio-Rad Laboratories). Briefly, cDNA was HNF1a regulation of UGT1A1, UGT1A9 and UGT2B7 J Ramírez et al amplified in 25 ml of reaction buffer containing IQSYBR Green Supermix, 0.5 mM of specific primers and nuclease-free water. The oligonucleotide sequences of the primers used are shown in Table 3 . Reactions were performed in triplicate and included standard curves for both the target and control genes. After preheating (hot start reaction) at 951C for 10 min, real-time PCR amplifications of the target genes were performed as follows: 40 cycles with melting at 951C for 30 s, annealing at 551C for 1 min and extension at 721C for 30 s. Data were collected as end points at 551C. Real-time PCR amplifications for 18S were performed as follows: preheating (hot start reaction) at 951C for 10 min, 40 cycles with melting at 951C for 15 s, and annealing and extension at 601C for 1 min. Data were collected as end points at 601C. A disassociation curve was used to confirm the specificity of the PCR product. The thermal profile for the disassociation curve was 951C for 1 min to denature the DNA, followed by 551C for 30 s. A ramp up to 951C was then applied. Data collection was performed during the ramp. Initial template quantities (ng/reaction) were calculated using threshold cycle (Ct) values and a standard curve.
Genotyping
Genotyping of HNF1a 79A4C was performed by single base extension (SBE) and denaturing high-performance liquid chromatography (DHPLC). Hepatic genomic DNA was amplified by PCR using a GeneAmp PCR System 9600 Thermal Cycler (Applied Biosystems). The amplification primer sequences were 5 0 -TTTCTAAACTGAGCCAGC-3 0 (forward) and 5 0 -GTCTCCCCCAGCCCATTG-3 0 (reverse). PCRs were set up in a 12.5 ml volume containing 125 nM of each primer, 25 ng of genomic DNA, 2.5 mM of MgCl 2 , 50 mm of each dNTP and 0.3 U of AmpliTag Gold polymerase (Applied Biosystems) in the buffer provided by the manufacturer. Reactions were denatured initially at 951C for 15 min then followed by 40 cycles of 951C for 15 s, 581C for 15 s and 721C for 45 s, and a final extension at 721C for 10 min. To remove unincorporated dNTPs and primers, the PCR product (10 ml) was mixed with 1 U of shrimp alkaline phosphatase and 1 U of exonuclease I in 1 Â of shrimp alkaline phosphatase buffer, and incubated at 371C for 45 min. Inactivation of the enzymes was done by heating at 951C for 15 min. The SBE reaction (10 ml) contained 1 mM of extension primer (5 0 -GCTCACCCAGTGCCTGGA-3 0 ), 250 mM of each ddNTP, 6 ml of purified PCR product and 1.25 U of ThermoSequenase. The reaction was run under the following conditions: 961C for 2 min, followed by 60 cycles at 961C for 30 s, 551C for 30 s and 601C for 30 s. Separation of the SBE products was performed after denaturation of samples (at 961C for 4 min) on a WAVE 3500HT DHPLC system (Transgenomic Inc., Omaha, NE, USA) at 701C. The gradient used for elution of the SBE products from the DNASep column (Transgenomic Inc.) was created by the software based on the length of the extended product. The mobile phase consisted of 0.1 M triethylammonium acetate (A) and 25/75 acetonitrile/0.1 M triethylammonium acetate (B). The gradient changed from 74.9% A and 25.1% B to 64.9% A and 35.1% B over 2 min. The four bases at the 3 0 -end of the extended products were eluted according to hydrophobicity differences of the order CoGoToA.
The HNF1a tagging SNPs are listed in Table 4 . They were selected using HapMap data publicly available (CEPH Caucasian population, r 2 ¼ 0.8, minor allele frequency of 0.1) and the algorithm Tagger-pairwise tagging. Samples were genotyped by PCR and SBE-DHPLC. Some PCR amplicons contained two or three tagging SNPs while other SNPs were amplified in a duplex PCR reaction. The SBE reactions were done either by individual or duplex reaction. Some SBE products were mixed after the SBE reaction and run together in a duplex format on DHPLC (see Table 5 ). The primer sequences used for PCR and SBE in each genotyping assay are listed in Table 5 . Each primer was designed using the Oligo 4.0 software with the genomic sequence assembled from the RefSeq Gene NM_000545.3 in the UCSC genome browser. The primers were checked for specificity using BLAT in the UCSC genome browser and BLAST in the NCBI database. Each assay was also verified with the known genotype controls selected from HapMap samples. PCRs were performed in a 15 ml volume containing 125 nM of each Table 3 The oligonucleotide sequences of primers used for real-time PCR
Gene
Primer Sequence for real-time PCR 
A/C Intron 7 (9) rs3999413 C/T Intron 9 (10) rs1169306 C/T Intron 9 (11) rs1169307 T/C Intron 9
HNF1a regulation of UGT1A1, UGT1A9 and UGT2B7 Underlined base refers to the modified base to minimize 3 0 -end primer-dimers and hairpins.
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158 The Pharmacogenomics Journal primer, 2.5 mM MgCl 2 (except one amplicon which was adjusted to 2 mM MgCl 2 ), 50 or 100 mm of each dNTP, 0.375 U of AmpliTaq Gold polymerase (Applied Biosystems) and 30 ng of genomic DNA. Amplification was performed in a GeneAmp PCR System 9600 thermal cycler (Applied Biosystems) with an initial denaturing step at 951C for 15 min followed by 40 cycles of 951C for 15 s, appropriate annealing temperature (Ta) for 15 s and 721C for 30 s or 1 min, and a final extension step at 721C for 10 min. The Ta for the different amplicons is listed in Table 5 . Some conditions in the PCR reaction were adjusted due to the amplicon size or a duplex reaction. PCR products were purified by treatment with shrimp alkaline phosphatase and exonuclease I at 371C for 45 min before SBE reactions. SBE reactions were performed in a 12 ml volume containing 1 mM of SBE primer, 250 mM each of four ddNTPs, 1.5 U of ThermoSequenase (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) and 7.2 ml of purified PCR products. For the duplex SBE reaction, 1 mM of each extension primer was added to the total volume. Reactions were run in a 9600 Thermal Cycler under the following conditions: 91C for 2 min, followed by 60 cycles of 961C for 30 s, 551C for 30 s and 601C for 30 s (except one SBE was at Ta 501C for rs12427353). Samples were denatured at 961C for 4 min and held at 41C before separation of the SBE products on the WAVE 3500HT DHPLC system (Transgenomic Inc.). Nine microliters of SBE products of each sample or 18 ml of two mixed SBE products per sample were injected onto the DHPLC for analysis. The mobile phase consisted of 0.1 M triethylammonium acetate (A) and 25/75 acetonitrile/0.1 M triethylammonium acetate (B). Samples were run on a high throughput column (Transgenomic Inc.) with an oven temperature of 701C using a start gradient of 21.8 %B or 24.1 %B for 3 min (slope-5%B per min). The start gradient (%B) was adjusted depending on the length and GC content of the extension primer. The extended products were eluted of the order of CoGoToA dependent on the hydrophobicity differences of the four bases. In the duplex reaction, SBE products and unextended primers were designed to elute at different times and could be distinguished from each other. Controls of known genotype were included in each run.
The UGT2B7 intron 1 985A4G variant was genotyped also by SBE-DHPLC. The PCR and extension primers were 5 0 -GATTTCAGCCATACTCTCAACA-3 0 (forward), 5 0 -GAGTCCT CCAACAAAATCAAC-3 0 (reverse) and 5 0 -CTACTATTGAAG GTTTAAG-3 0 (reverse extension primer with one base modified underlined). PCRs were set up in a 15 ml volume containing 2.5 mM MgCl 2 , 100 mM each dNTP, 125 nM forward and reverse primers, 0.375 U AmpliTaq Gold (Applied Biosystems) and 25 ng of DNA. Reactions were denatured initially at 951C for 15 min then cycled at 951C for 15 s, 611C for 15 s, and 721C for 45 s for 40 cycles. For the SBE reaction, the PCR amplified product was treated with shrimp alkaline phosphatase (Roche Diagnostics Corporation, Indianapolis, IN, USA) and exonuclease I (USB Corporation, Cleveland, OH, USA) to remove excess dNTPs and primers. Purified PCR product (6 ml) was combined with 1 mM of extension primer, 250 mM each ddNTP and 1.25 U Thermo Sequenase (GE Healthcare Bio-Sciences Corp.) in a 10 ml volume, and denatured initially at 961C for 2 min followed by cycling at 961C for 30 s, 501C for 30 s and 601C for 30 s for 60 cycles. Samples were denatured at 961C for 4 min before separation of the extension products. Extension products were separated using the WAVE 3500HT DHPLC system (Transgenomic Inc.). The mobile phase consisted of 0.1 M triethylammonium acetate (A) and 25/ 75 acetonitrile/0.1 M triethylammonium acetate (B). Separation on the column was performed at 701C using a gradient of 76% A and 24%, to 62.5% A and 37.5% B over 2.7 min. The samples had been previously genotyped for UGT1A1 À53(TA) 647 (UGT1A1*28) and UGT1A9 À118T 9410 (UG-T1A9*1b).
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Statistics
The mRNA levels were expressed as the ratio of the target gene to the control gene, 18S. The coefficients of variation in the mRNA levels derived from triplicate determinations were within 21%. Ten out of 54 samples were excluded from analysis of UGT1A9 mRNA levels due to insufficient amount of mRNA. Quantification of HNF1a mRNA levels failed in one sample. Frequency distribution analyses and the Kolmogorov-Smirnov (KS) normality test showed that the distribution of the mRNA levels of the UGTs was not normal (UGT1A1 KS distance ¼ 0.23, P ¼ 0.006, n ¼ 54; UGT1A9 KS distance ¼ 0.29, P ¼ 0.001, n ¼ 44; UGT2B7 KS distance ¼ 0.25, P ¼ 0.003, n ¼ 54). The HNF1a mRNA levels were normally distributed (KS distance ¼ 0.11, P40.10, n ¼ 53). To normalize the data, the mRNA levels (including HNF1a, for consistency) were log-transformed before statistical analysis. Log-transformed data passed the normality test (P40.10).
Univariate linear regressions were used to select independent variables that could be possible predictors of UGT mRNA expression levels. We first investigated whether there was a correlation between the hepatic mRNA levels of HNF1a and those of each UGT. We also evaluated whether the mRNA levels of the UGTs correlated among each other. To explore whether the pair-wise correlations observed between the mRNA levels were related to 18S (present in the denominator), partial correlations were also performed. We investigated next the relationship between genotype and gene expression levels. Three univariate genetic models (additive, dominant and recessive) were tested, as the modes of inheritance were either unknown or not clearly identifiable from the plotted data. Linear regression analysis was also used to compare gene expression levels between females and males, and between donors who had ingested UGT inducers (phenobarbital and/ or dexamethasone, alcohol) or had smoked cigarettes, and those who did not. The variables with significant P-values (Pp0.1, based on the t-tests with the null hypothesis that the slope or r 2 ¼ 0) were then selected for multivariate 
